Patents Assigned to Shionogi & Co., Ltd.
  • Publication number: 20240400560
    Abstract: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Provided is a compound represented by Formula (I): wherein carbon atom a and carbon atom b are each a carbon atom constituting ring A, the ring A is substituted aromatic carbocycle or the like, R1 is substituted or unsubstituted aromatic heterocyclyl or the like, R2 is substituted or unsubstituted 6-membered aromatic carbocyclyl or the like, m is 1 or the like, R5as are each independently a hydrogen atom or the like, R5bs are each independently a hydrogen atom or the like, n is 1 or the like, R4a is a hydrogen atom or the like, and R4a is a hydrogen atom or the like. Alternatively, provided is a pharmaceutically acceptable salt of the compound.
    Type: Application
    Filed: September 15, 2022
    Publication date: December 5, 2024
    Applicants: Shionogi & Co., Ltd., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Yoshiyuki TAODA, Shota UEHARA, Yuseke SAKO, Keiichiro HIRAI
  • Publication number: 20240374587
    Abstract: A pharmaceutical preparation characterized by combination of (A) and (B) is useful for the prevention and treatment of a disease related to anti-obesity effect, wherein (A) is a compound represented by formula: or a pharmaceutically acceptable salt thereof, and (B) is at least one agent selected from the group consisting of agents having anti-obesity action, agents for controlling blood glucose level, agents for controlling cholesterol and/or triglyceride in blood, and agents for controlling blood pressure.
    Type: Application
    Filed: September 7, 2022
    Publication date: November 14, 2024
    Applicant: Shionogi & Co., Ltd.
    Inventors: Kosuke TAKEMOTO, Keisuke KUSUMOTO
  • Patent number: 12139489
    Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.
    Type: Grant
    Filed: March 22, 2023
    Date of Patent: November 12, 2024
    Assignee: Shionogi & Co., Ltd.
    Inventors: Yoshiyuki Taoda, Yuto Unoh
  • Publication number: 20240366622
    Abstract: The present invention provides a preparation that is minimally colored through irradiation with light by coating a preparation containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or a crystal thereof with a light stabilizing substance and a polymer, particularly with one or more of titanium oxide and talc used as the light stabilizing substance and hypromellose used as the polymer.
    Type: Application
    Filed: July 15, 2024
    Publication date: November 7, 2024
    Applicant: Shionogi & Co., Ltd.
    Inventors: Naomi HAYASHI, Masato GOMI, Shohei AIKAWA
  • Publication number: 20240352015
    Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.
    Type: Application
    Filed: June 26, 2024
    Publication date: October 24, 2024
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yoshiyuki TAODA, Yuto UNOH
  • Patent number: 12098151
    Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: September 24, 2024
    Assignees: NATIONAL UNIVERSITY COPORATION HOKKAIDO UNIVERSITY, SHIONOGI & CO., LTD.
    Inventors: Akihiro Ishii, Akihiko Sato, Makoto Kawai, Yoshiyuki Taoda
  • Publication number: 20240309002
    Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like; y is 0 or 1; R1 is hydrogen or the like; R2a and R2b are taken together with an adjacent carbon atom to form ring B; ring B is a substituted or unsubstituted non-aromatic carbocycle or the like; R3a is hydrogen or the like; R3b is hydrogen or the like; R4a is represented by formula: L1 is a single bond or the like; L2 is —C(?O)— or the like; La is a single bond or the like; R7 is substituted or unsubstituted alkyl or the like; R4b is substituted or unsubstituted alkyl or the like; R4c is each independently halogen or the like.
    Type: Application
    Filed: May 16, 2024
    Publication date: September 19, 2024
    Applicant: Shionogi & Co., Ltd.
    Inventors: Kouhei NODU, Yusuke Tateno, Kengo Masuda, Yuji Nishiura, Yoshikazu Sasaki, Yu Hinata
  • Publication number: 20240279238
    Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
    Type: Application
    Filed: April 9, 2024
    Publication date: August 22, 2024
    Applicants: Shionogi & Co., Ltd., ViiV Healthcare Company
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
  • Patent number: 12064438
    Abstract: The present invention provides a preparation that is minimally colored through irradiation with light by coating a preparation containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or a crystal thereof with a light stabilizing substance and a polymer, particularly with one or more of titanium oxide and talc used as the light stabilizing substance and hypromellose used as the polymer.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: August 20, 2024
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Naomi Hayashi, Masato Gomi, Shohei Aikawa
  • Publication number: 20240252505
    Abstract: The present invention provides a solid dosage form having good stability, suspensibility in water and fluidity by preparing a solid dosage form containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stabilizer, a sugar alcohol and/or a sugar, a water-soluble polymer and an inorganic substance.
    Type: Application
    Filed: February 7, 2024
    Publication date: August 1, 2024
    Applicant: Shionogi & Co., Ltd.
    Inventors: Naoya MIZUTANI, Masayuki MORIMOTO, Maki OKABE, Masaaki ITO, Go KIMURA
  • Publication number: 20240217966
    Abstract: The present invention relates to a compound that has GLP-1 receptor agonist activity and is useful as a therapeutic or prophylactic agent for diseases associated with the GLP-1 receptor, or a pharmaceutically acceptable salt thereof, and relates to a pharmaceutical composition containing the compound or its pharmaceutically acceptable salt. Provided is a compound represented by formula (I): wherein A1 is C(R5) or the like, A2 is C(R6) or the like, A3 is C(R7) or the like, R5, R6, and R7 are each independently a hydrogen atom or the like, R1 is carboxy or the like, R2 is substituted or unsubstituted alkyl or the like, —X— is —O— or the like, the ring represented by: is a ring represented by: ?and the like wherein R10 is each independently halogen or the like, s is 0 or the like, R13 is each independently a hydrogen atom or the like, and R3 is substituted or unsubstituted aromatic carbocyclyl or the like, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 23, 2022
    Publication date: July 4, 2024
    Applicant: Shionogi & Co., Ltd.
    Inventors: Misato KITAMURA FUJIWARA, Shomitsu MAENO, Yuji NISHIURA
  • Patent number: 12024519
    Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: is or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: July 2, 2024
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Kouhei Nodu, Yusuke Tateno, Kengo Masuda, Yuji Nishiura, Yoshikazu Sasaki
  • Publication number: 20240190975
    Abstract: The chimeric antigen receptor that recognizes CCR8 as an antigen of the present invention has cytotoxic activity against CCR8-expressing cells by being expressed in effector cells.
    Type: Application
    Filed: March 31, 2022
    Publication date: June 13, 2024
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Mai Yoshikawa, Miya Haruna, Morio Nagira, Koji Takahashi, Marina Hayashida, Hiroto Miwa, Yudai Sonoda, Naganari Ohkura, Shimon Sakaguchi, Hisashi Wada
  • Publication number: 20240182463
    Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.
    Type: Application
    Filed: August 4, 2023
    Publication date: June 6, 2024
    Applicant: Shionogi & Co., Ltd.
    Inventors: Chika TAKAHASHI, Hidenori MIKAMIYAMA, Toshiyuki AKIYAMA, Kenji TOMITA, Yoshiyuki TAODA, Makoto KAWAI, Kosuke ANAN, Masayoshi MIYAGAWA, Naoyuki SUZUKI
  • Publication number: 20240180954
    Abstract: The present invention provides novel cationic lipids having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by Formula (I) or a pharmacologically acceptable salt thereof. In the Formula (I), R1 is a substituted or unsubstituted formula: (CH2)a—L1—(CH2)b—CH3; R2 is a substituted or unsubstituted C5-C20 alkyl group or a substituted or unsubstituted formula: —(CH2)c—L2—(CH2)a—CH3; L1 and L2 are each independently —C(?O)O—, —OC(?O)—, or —OC(?O)O—; a, b, c, and d are each independently an integer of at least 1, and the total of a and b and the total of c and d are each an integer of 5 to 25; R3 to R7 are each independently a hydrogen atom, a substituted or unsubstituted C1-C6 alkyl group, or the like; R8, R9, and R10 are each a hydrogen atom; the constituent atoms in the Formula (I) may form a ring; Z is —OC(?O)—, —C(?O)O—, —OC(?O)O—, or the like; and X is O or S.
    Type: Application
    Filed: February 2, 2022
    Publication date: June 6, 2024
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Akira KUGIMIYA, Jun NAKAMURA, Norikazu KURODA, Tetsuya TANINO, Atsushi HAYATA, Ippei MORITA, Shun KITAHATA
  • Publication number: 20240150853
    Abstract: The present invention provides a method for quantitatively detecting virus-derived RNA and/or DNA in an environmental sample or a fecal sample with high sensitivity, and a kit for quantitatively detecting virus-derived RNA and/or DNA in an environmental sample or a fecal sample with high sensitivity.
    Type: Application
    Filed: February 25, 2022
    Publication date: May 9, 2024
    Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Shionogi & Co., Ltd.
    Inventors: Masaaki KITAJIMA, Ryo IWAMOTO, Yusaku MASAGO, Shin HAYASE, Yuka KATAYAMA ADACHI
  • Publication number: 20240148741
    Abstract: The present invention provides a formulation for oral administration, comprising a triazine derivative having virus proliferation inhibitory action.
    Type: Application
    Filed: November 22, 2022
    Publication date: May 9, 2024
    Applicant: Shionogi & Co., Ltd.
    Inventors: Masato GOMI, Kensuke HORIUCHI, Masayuki MORIMOTO, Keisuke TAKAGAKI
  • Publication number: 20240092784
    Abstract: A condensed heterocyclic compound has a sepiapterin reductase inhibitory action and is particularly useful for treatment of a pain. The condensed heterocyclic compound represented by Formula (I) below (R1 represents a hydrocarbon group or the like; R2 and R3 represent a hydrogen atom or the like; R4, X, and Y represent defined substituents), a tautomer or a pharmaceutically acceptable salt of the compound, or a solvate of any of these.
    Type: Application
    Filed: April 13, 2021
    Publication date: March 21, 2024
    Applicants: NISSAN CHEMICAL CORPORATION, SHIONOGI & CO., LTD.
    Inventors: Masahiro KAMAURA, Yusuke INABA, Yusuke SHINTANI, Yuki KUWANO, Moemi NAKAO, Hiroshi NAGAI, Noriyuki KUROSE, Kenji TAKAYA, Mado NAKAJIMA
  • Patent number: 11932696
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: March 19, 2024
    Assignees: SHIONOGI & CO., LTD., OSAKA UNIVERSITY
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Publication number: 20240083872
    Abstract: Provided are a compound having serotonin 5-HT2A receptor antagonism and/or inverse agonism, a pharmaceutically acceptable salt thereof, and a composition for serotonin 5-HT2A receptor antagonism and/or inverse agonism comprising them.
    Type: Application
    Filed: December 27, 2021
    Publication date: March 14, 2024
    Applicant: Shionogi & Co., Ltd.
    Inventor: Kenji NAKAHARA